| scholarly article | Q13442814 |
| P50 | author | Greg N. Fuller | Q37370656 |
| Francisco J Esteva | Q43937223 | ||
| Wendy A Woodward | Q61037731 | ||
| P2093 | author name string | Thomas A Buchholz | |
| Susan L Tucker | |||
| Michael Z Gilcrease | |||
| Marlo M Nicolas | |||
| Lynda J Corley | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q34184177 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients | Q36614830 | ||
| Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer | Q36617556 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. | Q38453585 | ||
| Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer | Q38463900 | ||
| Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up | Q38490688 | ||
| Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer | Q41756399 | ||
| HER-2/neu oncogene protein and prognosis in breast cancer | Q41927421 | ||
| Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. | Q43643447 | ||
| A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up | Q44454004 | ||
| Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer | Q44927602 | ||
| Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients | Q46580491 | ||
| Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule | Q50773376 | ||
| Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer | Q59616875 | ||
| HER-2/neu amplification predicts poor survival in node-positive breast cancer | Q68091225 | ||
| Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer | Q68301337 | ||
| c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases | Q71692738 | ||
| Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy | Q72675847 | ||
| Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome | Q73205060 | ||
| erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer | Q77331949 | ||
| erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer | Q77331953 | ||
| Inconsistency of HER2 test raises questions | Q80595700 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 759-767 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | The American Journal of Surgical Pathology | Q7713508 |
| P1476 | title | Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer | |
| P478 | volume | 33 |
| Q60044026 | BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score |
| Q58786250 | Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers |
| Q37613953 | Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer |
| Q40951473 | Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer |
| Q24810389 | ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer |
| Q34133760 | ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis |
| Q38832170 | Expression analysis of four long noncoding RNAs in breast cancer |
| Q34981712 | HER2 as a promising target for cytotoxicity T cells in human melanoma therapy |
| Q37317064 | Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism |
| Q44541840 | Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research |
| Q64115873 | Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association |
| Q36405652 | Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer |
| Q53523972 | Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. |
| Q40453735 | Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. |
| Q33862786 | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update |
| Q37993442 | Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis |
| Q34424285 | Testing for HER2 in Breast Cancer: A Continuing Evolution |
| Q35201328 | The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease |
| Q54676467 | [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. |
Search more.